4 results
This study will investigate whether oligometastatic triple negative or BRCA1/2 related breast cancer can be treated effectively with a multimodality approach including induction chemotherapy, and whether high dose alkylating chemotherapy can improve…
This phase II/III controlled multicenter trial will investigate the ability of individualized chemotherapy to improve the objective response rate of *triple-negative* breast cancer (estrogen receptor and progesterone receptor-negative, no HER2…
This study will investigates the effect of high dose alkylating chemotherapy compared to standard dose chemotherapy as part of a multimodality approach in patients with oligometastatic HRD positive and/or BRCA1/2 related breast cancer.
To investigate whether (neo)adjuvant systemic treatment of intensified alkylating chemotherapy with peripheral stem cell rescue (mini-CTC) compared to AC-CP chemotherapy followed by 1-year olaparib monotherapy substantially improves overall survival…